Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and/or female subjects between the ages of 18 and 55 years.~* Recreational polydrug user with a history of CNS depressant use.~Exclusion Criteria:~* History of clinically significant neurologic condition(s), such as seizures, convulsions, epilepsy, or significant head injury, as judged by the investigator or designee.~* A known history of hypersensitivity or previous intolerance to dimebon or other antihistamines.~* Self-reported history of drug or alcohol dependence (except nicotine or caffeine) in the 2 years prior to screening, or drug or alcohol dependence as defined by the (DSM-IV-TR) in 12 months prior to screening, including subjects who have ever been in a substance rehabilitation program (other than treatment for smoking cessation).~* History of clinically significant psychiatric disorder(s), as judged by the investigator or qualified designee.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- dimebon 20 mg (Type: EXPERIMENTAL): None
- dimebon 40 mg (Type: EXPERIMENTAL): None
- dimebon 60 mg (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None
- alprazolam 1 mg (Type: ACTIVE_COMPARATOR): None
- alprazolam 3 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).